Related Experiment Video
Updated: Jul 31, 2025
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on Target
Shannon A Carty1, Carlos A Murga-Zamalloa2, Ryan A Wilcox1
1Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI.
Abstract:
While the peripheral T-cell lymphomas (PTCL) remain a therapeutic challenge, and increasingly account for a disproportionate number of lymphoma-related deaths, improved understanding of disease pathogenesis and classification, and the development of novel therapeutic agents over the past decade, all provide reasons for a more optimistic outlook in the next. Despite their genetic and molecular heterogeneity, many PTCL are dependent upon signaling input provided by antigen, costimulatory, and cytokine receptors. While gain-of-function alterations effecting these pathways are recurrently observed in many PTCL, more often than not, signaling remains ligand-and tumor microenvironment (TME)-dependent. Consequently, the TME and its constituents are increasingly recognized as "on target". Utilizing a "3 signal" model, we will review new-and old-therapeutic targets that are relevant for the more common nodal PTCL subtypes.
Insights
Peripheral T-cell lymphomas (PTCL) are challenging to treat but new insights into their biology and novel therapies offer hope. Many PTCL rely on signaling pathways influenced by the tumor microenvironment (TME), presenting new therapeutic targets.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Peripheral T-cell lymphomas (PTCL) represent a significant clinical challenge, contributing disproportionately to lymphoma-related mortality.
- Despite molecular heterogeneity, PTCL pathogenesis often involves dysregulated signaling from antigen, costimulatory, and cytokine receptors.
- The tumor microenvironment (TME) and its components are increasingly recognized as critical drivers and potential therapeutic targets in PTCL.
Purpose of the Study:
- To review current and emerging therapeutic targets for common nodal PTCL subtypes.
- To highlight the role of signaling pathways and the TME in PTCL development and progression.
- To provide an updated perspective on PTCL treatment strategies based on a "3 signal" model.
Main Methods:
- Review of existing literature on PTCL pathogenesis, classification, and therapeutic strategies.
- Analysis of signaling pathways (antigen, costimulatory, cytokine receptors) crucial for PTCL survival.
- Integration of the tumor microenvironment (TME) as a key factor in PTCL signaling and therapeutic targeting.
Main Results:
- PTCL signaling pathways are often ligand- and TME-dependent, despite recurrent gain-of-function alterations.
- The TME and its constituents are validated as crucial "on target" elements for therapeutic intervention.
- A "3 signal" model framework is proposed for understanding PTCL dependencies.
Conclusions:
- Improved understanding of PTCL biology, including TME interactions, enhances therapeutic prospects.
- Novel therapeutic agents targeting key signaling pathways and the TME offer a more optimistic outlook for PTCL treatment.
- Focusing on TME-dependent signaling provides a rational approach to developing new therapies for nodal PTCL subtypes.
